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ABSTRACT
Spinal Muscular atrophy is a prevalent genetic disease caused by mutation of the SMN1 gene, which encodes the SMN protein
involved in assembly of small nuclear ribonucleoprotein (snRNP) complexes. A paralog of the gene, SMN2, cannot provide
adequate levels of functional SMN because exon 7 is skipped in a significant fraction of the mature transcripts. A C to T
transition located at position 6 of exon 7 is critical for the difference in exon skipping between SMN1 and SMN2. Here we
report that this nucleotide difference results in increased ultraviolet light-mediated crosslinking of the splicing factor U2AF65
with the 39 splice site of SMN1 intron 6 in HeLa nuclear extract. U2 snRNP association, analyzed by native gel electrophoresis,
is also more efficient on SMN1 than on SMN2, particularly under conditions of competition, suggesting more effective use of
limiting factors. Two trans-acting factors implicated in SMN regulation, SF2/ASF and hnRNP A1, promote and repress,
respectively, U2 snRNP recruitment to both RNAs. Interestingly, depending on the transcript and the regulatory factor, the
effects on U2 binding not always correlate with changes in U2AF65 crosslinking. Furthermore, blocking recognition of a Tra2-
b1-dependent splicing enhancer located in exon 7 inhibits U2 snRNP recruitment without affecting U2AF65 crosslinking.
Collectively, the results suggest that both U2AF binding and other steps of U2 snRNP recruitment can be control points in SMN
splicing regulation.
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INTRODUCTION
Spinal muscular atrophy (SMA) is the most common
genetic cause of infant mortality, with an incidence of
approximately one in 6000 live births. This neuromuscular
disorder progressively affects motor neurons in the anterior
horns of the spinal cord, leading to muscular atrophy and
paralysis (for review, see Russman 2007). Homozygous
loss-of-function mutations in the SMN1 gene are the cause
of SMA (Lefebvre et al. 1995). SMN1 encodes the SMN
protein, which forms, together with seven Gemin proteins,
the SMN complex (for review, see Gubitz et al. 2004). The
SMN complex is involved in the assembly of Sm proteins
on most U-rich small nuclear RNAs (U snRNAs), an
essential step in U-rich small nuclear ribonucleoprotein
particle (U snRNP) biogenesis (for review, see Will and
Lu¨hrmann 2005). SMN deficiency causes tissue-specific
perturbations in the repertoire of snRNAs and widespread
defects in splicing that are believed to underpin the
molecular pathology of SMA (Zhang et al. 2008).
The SMN1 gene is located in the complex chromosomal
region 5q13 (Brzustowicz et al. 1990; Melki et al. 1990)
which in humans contains a large inverted duplication,
with a second, more centromeric copy of SMN1, the SMN2
gene. Of relevance for SMA, the SMN2 gene cannot fully
substitute for SMN1 because exon 7 is frequently skipped in
SMN2, but not in SMN1 transcripts (Monani et al. 1999).
Exon 7 skipping generates a truncated, SMN2D7 protein
isoform, which can only provide limited SMN function (Le
et al. 2005). Several nucleotide differences exist between the
genomic sequence of SMN1 and SMN2 genes, and two of
them have been implicated in increased skipping of exon 7
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in SMN2 transcripts, a critical translationally silent C to T
transition at position 6 of exon 7 (Lorson et al. 1999) and
an A to G transition at position 100 of intron 7 (Kashima
et al. 2007a). Because the extent of SMN2 exon 7 skipping,
which is variable in SMA patients, has been correlated with
disease severity (Mailman et al. 2002), modulation of this
splicing event has been proposed as a potential therapy for
the disease. Indeed, various strategies have been utilized to
harness SMN2 exon 7 inclusion that led to restoration of
SMN function in cells in culture and correction of SMN2
splicing in transgenic mice. These include methods that
enhance exon 7 recognition using synthetic exon-specific
peptide–nucleic acid activators or bifunctional antisense
oligonucleotides (Cartegni and Krainer 2003; Skordis et al.
2003), or antisense oligonucleotides that antagonize a
silencer sequence (Hua et al. 2008). Additional strategies
have included reducing the competitiveness of the exon 8 39
splice site (Madocsai et al. 2005) or employing trans-
splicing to redirect SMN2 splicing (Coady et al. 2007).
Given this potential, understanding the molecular mech-
anisms underlying differential splicing of SMN1 and SMN2
is of considerable interest. The sequence elements required
for exon 7 inclusion in the SMN1 and SMN2 genes have
been the subject of intensive studies, including systematic
mutagenesis of exonic sequences and antisense oligonucle-
otide tiling methods (for review, see Singh 2007; Hua et al.
2008). One concept emerging from these studies is that the
sequences in and around SMN exon 7 are dense in splicing
regulatory elements. Thus, several splicing enhancers have
been defined in exon and intron 7, including a Tra2-b1
enhancer in the central region of the exon which binds
Tra2-b1, SRp30c, and hnRNP G (Hofmann et al. 2000;
Young et al. 2002; Hofmann and Wirth 2002). Several
splicing silencers have also been identified in exon 7 and
flanking introns (Singh et al. 2004, 2006; Hua et al. 2007,
2008). One key question is how the interplay between these
regulatory elements is affected by the nucleotide differences
between SMN1 and SMN2 that cause more extensive
skipping of exon 7 in SMN2 transcripts (Lorson et al.
1999; Kashima et al. 2007a).
In this study we focused on how the C to T nucleotide
substitution at position +6 of SMN exon 7 influences 39
splice site recognition by the basic splicing machinery. It
has been proposed that the T +6 substitution weakens a
splicing enhancer recognized by the splicing factor SF2/ASF
(Cartegni and Krainer 2002; Cartegni et al. 2006). SF2/ASF
belongs to the SR family of splicing regulatory factors
characterized by the presence of one or two RNA-recogni-
tion motifs and a C-terminal domain with multiple al-
ternating arginine and serine-dipeptides (for review, see Lin
and Fu 2007). One classical function of SR proteins bound
to exonic sequences is to stimulate recognition of the
flanking splice sites (for review, see Singh and Valca´rcel
2005). 39 splice sites are initially recognized by the branch-
point binding protein (BBP/SF1) and the 65 and 35 kDa
subunits of the U2 Auxiliary Factor U2AF (for review, see
Will and Lu¨hrmann 2005). Enhancer-bound SR proteins
can promote U2AF65 binding to the polypyrimidine tract
that precedes the conserved AG dinucleotide present at the
39 end of the intron (Zuo and Maniatis 1996; Zhu and
Krainer 2000). The results from other experiments, includ-
ing tethering of RS domains through heterologous RNA–
protein interactions, suggest that other steps in U2 snRNP
assembly and even late steps of the splicing process can be
stimulated by exonic enhancers and RS domains (Chew
et al. 1999; Guth et al. 1999; Kan and Green 1999; Shen and
Green 2004; Shen et al. 2004). Splicing enhancers can also
stimulate splicing by modulating the activity of inhibitory
complexes (Zhu et al. 2001).
Another model proposes that the T +6 substitution
creates a splicing silencer sequence in SMN2 exon 7, which
is recognized by hnRNP A1 (Kashima and Manley 2003;
Cartegni et al. 2006; Kashima et al. 2007b). Binding of
hnRNP proteins to intronic and exonic sequences has been
correlated with inhibition of neighboring (or intervening)
splice sites (for review, see Singh and Valca´rcel 2005).
hnRNP A1 has been shown to reduce the early association
of splicing factors (Eperon et al. 2000), but can also tar-
get later events in spliceosome assembly, depending on the
pre-mRNA substrate (Tange et al. 2001). The inhibitory
function of hnRNP A1 and possibly other hnRNP proteins
often requires homotypic cooperative interactions between
RNA-bound molecules, and may be based upon looping
out the intervening region of the RNA and/or multimeri-
zation of the hnRNP proteins from a high-affinity site to
create a silenced region in the pre-mRNA (Blanchette and
Chabot 1999; Zhu et al. 2001; Wagner and Garcia-Blanco
2001). Decreased occupancy of a regulated 39 splice site by
U2AF has been reported upon phosphorylation of the
splicing regulator Sam68 by the ERK–MAP kinase pathway
(Tisserant and Ko¨nig 2008).
The combinatorial effects of enhancers and silencers, as
well as their mutual influences, determine the extent of
association of splicing factors with the pre-mRNA. In this
manuscript we have tested whether differential recognition
of SMN1 and SMN2 exon 7 can be correlated with dif-
ferential recruitment of U2AF and U2 snRNP to the 39
splice site of this exon, as well as the effects of SF2/ASF,
hnRNP A1, and a Tra2-b1-dependent exonic enhancer on
these events. Our results suggest that both U2AF and U2
snRNP binding can be control points in SMN splicing
regulation.
RESULTS
U2AF binding to SMN1 and SMN2 RNAs
It has been proposed that the higher level of exon 7 inclu-
sion in SMN1 transcripts compared with SMN2 transcripts
is due to more efficient recruitment of U2AF to the SMN1
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intron 6 39 splice site (Kashima and Manley 2003; Cartegni
et al. 2006). To test this hypothesis, we first confirmed that
recognition of SMN1 and SMN2 intron 6 by U2 snRNP
requires U2AF (Supplemental Fig. 1), as is the case for
most, but not all 39 splice sites (MacMillan et al. 1997;
Lutzelberger et al. 2005; Sridharan and Singh 2007).
Second, we tested whether the U2AF intrinsic binding
affinity is higher for SMN1 than for SMN2 transcripts.
Radioactively labeled RNAs comprising the 39 68 nucleo-
tides (nt) of SMN intron 6, SMN1, or SMN2 exon 7 (54 nt)
and 25 nt of intron 7 were incubated with purified
recombinant U2AF65, or partially purified U2AF hetero-
dimer from HeLa cells, in the presence of an excess of
unrelated RNA (tRNA). RNA–protein complexes were then
resolved by electrophoresis in native gels. To avoid non-
specific RNA–protein interactions mediated by the posi-
tively charged RS domain expressed in Escherichia coli (Lee
et al. 1993; Singh et al. 1995), a U2AF65 derivative lacking
the RS domain region was used in these experiments. As
expected from the reported binding specificity of U2AF for
polypyrimidine tracts (Singh et al. 1995), U2AF65 and the
partially purifed U2AF heterodimer displayed comparable
apparent binding affinities for the SMN1 and SMN2 RNAs
utilized, which differ only at position 6 of exon 7 (Fig.
1A,B).
Next, the possibility that additional factors, differentially
recruited to SMN1 and SMN2 RNAs, influence U2AF
binding was addressed using ultraviolet light (UV)-induced
crosslinking/immunoprecipitation. The 32P-uridine labeled
RNAs described above were incubated with HeLa nuclear
extract, irradiated with short wavelength UV-light, and
after RNase A digestion, U2AF65 was immunoprecipitated
using the specific MC3 monoclonal antibody (Gama-
Carvalho et al. 1997). Radioactively labeled U2AF65 was
identified by electrophoresis on SDS gels and Phosphor-
Imager analysis. First, the specificity of U2AF65 crosslinking
for the polypyrimidine tract of intron 6 was assessed using
mutant versions of the RNAs in which uridine residues in
the region upstream of exon 7 were replaced by cytidines
(Fig. 2A, Py-mut). The results of Figure 2C indicate that
U2AF65 crosslinking to both SMN1 and SMN2 wild-type
transcripts was readily detectable, while crosslinking to the
py-mut RNAs was not, indicating that the crosslinking
signal reflects specific interaction of U2AF65 with the Py-
tract region of SMN1 and SMN2 intron 6. To verify that the
crosslinking/immunoprecipitation assay was quantitative,
we performed the assay using increasing concentrations of
nuclear extract. The results of Figure 2D show that
increasing concentrations of nuclear extract resulted in
increased levels of U2AF65 crosslinking to SMN1 and SMN2
RNAs, indicative of the quantitative nature of the assay.
Importantly, the extent of U2AF65 crosslinking to SMN1
was consistenly higher than to SMN2 RNA (Fig. 2D, cf.
lanes 1 and 4, cf. lanes 2 and 5, cf. lanes 3 and 6). Because
the overall pattern of protein crosslinking in nuclear extract
is comparable for both RNAs (Fig. 2B), the difference
observed in U2AF65 crosslinking is specific for the interac-
tion between this protein and SMN1 and SMN2 transcripts.
Figure 2E quantifies the results of several independent
experiments confirming the approximately twofold higher
levels of crosslinking of U2AF65 to the SMN1 than to the
SMN2 intron 6 39 splice site. Time course experiments
indicated that the differences in U2AF65 crosslinking are
not due to different kinetics of association of U2AF65 with
SMN1 and SMN2 transcripts (data not shown).
We note that differences in U2AF65 crosslinking to
SMN1 and SMN2 transcripts were detected in extracts that
also showed differences in the relative inclusion of exon 7
between SMN1 and SMN2 in in vitro splicing assays (using
minigenes spanning SMN genomic sequences between exon
6 and exon 8) (Supplemental Fig. 2; Cartegni and Krainer
2002). Nuclear extracts that, for unknown reasons (but
unrelated to the relative levels of U2AF, SF2/ASF, or
hnRNP A1), failed to recognize SMN1 or SMN2 exon 7,
displayed equivalent levels of U2AF65 crosslinking to SMN1
and SMN2 RNAs (Supplemental Figs. 2, 3). This correla-
tion suggests that differential U2AF recruitment to intron 6
is relevant for differential exon 7 recognition in SMN
transcripts.
U2 snRNP assembly on SMN1 and SMN2 RNAs
To investigate whether the differential binding of U2AF65
to SMN1 and SMN2 transcripts has subsequent effects on
the assembly of other spliceosomal components around
SMN exon 7, the same radioactively labeled RNAs were
FIGURE 1. Intrinsic U2AF affinity is similar for SMN1 and SMN2.
32P-radioactively labeled SMN1 or SMN2 exon 7 pre-mRNAs con-
taining the 39 68 nt of intron 6, exon 7 sequences, and 25 nt of intron
7, were incubated with increasing concentrations (30, 90, and 270
nM) of recombinant U2AF65 lacking the RS domain (DRS–U2AF65)
(A) or endogenous U2AF partially purified from HeLa nuclear extract
(GUA-guanidine eluate from oligo-dT cellulose columns used to
prepare U2AF-depleted extracts) (B). Complexes were assembled on
ice and RNA–protein complexes fractionated by electrophoresis on
native polyacrylamide gels at 4°C. The positions of unbound–RNA
and RNA–protein complexes are indicated.
Differential 39 splice site recognition of SMN
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incubated with nuclear extract under splicing conditions
and after heparin treatment, splicing complexes were
resolved by electrophoresis on native polyacrylamide/aga-
rose gels. The extent and kinetics of ATP-dependent
complex A formation (which reflects stable binding of U2
snRNP on to the 39 splice site region) showed an average
difference of 1.6-fold between SMN1 and SMN2 (Fig. 3A,
D, lane 1, P value=0.03). This difference is somewhat lower
than the difference observed for U2AF65 crosslinking to
these transcripts (Fig. 2).
We next considered the possibility that differences in
spliceosome assembly could become more prominent under
conditions of competition for factors involved in U2 snRNP
binding, which may mimic more accurately the conditions
of splice-site competition operating during splice-site selec-
tion. Spliceosome assembly assays were therefore carried
out in the presence of increasing amounts of unlabeled
competitor. The results of Figure 3B and the quantifications
of Figure 3C indicate that SMN1 RNA is a better competitor
than SMN2 RNA in this assay: unlabeled SMN1 competed
more efficiently than SMN2 the assembly of complexes on
either radiolabeled-SMN1 or -SMN2 RNAs (Fig. 3B, levels
FIGURE 2. Higher levels of U2AF65 crosslinking to SMN1 intron 6
polypyrimidine-tract. (A) Sequences of the SMN intron 6 39 splice site
region and a mutant derivative (Py-mut) in which uridine residues at
the polypyrimidine tract (Py-tract) were replaced by cytidines. Exon 7
position 6, different between SMN1 (C) and SMN2 (T) transcripts is
also indicated. (B) Pattern of proteins from HeLa nuclear extracts
crosslinked to SMN transcripts upon irradiation with UV light. 32P-
uridine-labeled RNAs (SMN1 or SMN2, wild type or Py-mut, as
indicated) containing the 39 68 nt of intron 6, exon 7 sequences, and
25 nt of intron 7 were incubated with nuclear extracts, and after UV
irradiation and RNAse treatment, 10% of the crosslinked material was
fractionated on a SDS-polyacrylamide gel and analyzed by Phosphor-
Imager. (C) U2AF65 immunoprecipitation. 90% of the products of
crosslinking obtained as in B were immunoprecipitated using the anti-
U2AF65 antibody MC3, or a control monoclonal antibody (104).
Immunoprecipitated materials were fractionated on SDS denaturing
gels and analyzed by PhosporImager. The positions of molecular
weight markers and U2AF65 are indicated. (D) UV-crosslinking and
U2AF65 immunoprecipitation with increasing amounts of nuclear
extracts (NE). Assays were carried out as in (C) using 1.3%, 4%, and
12% of nuclear extracts. (E) Ratio of U2AF65 crosslinking to SMN1
versus SMN2 transcripts, quantified by PhosphorImager analyses,
corresponding to three independent experiments. Error bar represents
standard deviation.
FIGURE 3. U2 snRNP recruitment to SMN1 and SMN2 RNAs. (A)
Time-course of spliceosome assembly on SMN1 and SMN2 exon 7
pre-mRNAs. RNAs containing the 39 68 nt of intron 6, exon 7, and 25
nt of intron 7 were incubated with HeLa nuclear extracts under
splicing conditions and after 30 min complexes were analyzed by
electrophoresis on native polyacrylamide/agarose gels. The positions
of A complex (U2 snRNP binding to intron 6 39 splice site region) and
H complex (hnRNP proteins bound to the same RNA) are indicated.
(B) Spliceosome assembly under conditions of competition. Assays
were set up as in A in the absence or presence of 10, 20, or 40 ng of
the indicated unlabeled RNAs. (C) Quantification of the results
of independent competition experiments carried out as in B. The
efficiency of complex A formation (A/H ratios) on 32P-labeled SMN1
or SMN2 in the presence of competitor RNAs relative to assembly in
the absence of competitor is represented for four independent
experiments. (D) Relative levels of A complex formation on SMN1
versus SMN2. Ratios of A/H complex formation on SMN transcripts
in the absence or presence of competitor RNAs are represented. Bars
indicate standard deviations. P values for the null hypothesis that
complex A assembly is identical on SMN1 and SMN2 are 0.03 (in the
absence of competitor) and lower than 0.001 (in the presence of either
competitor).
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of A complex, cf. lanes 5 and 8, cf. lanes 11 and 14, cf. lanes
12 and 15, cf. lanes 13 and 16; Fig. 3C, stronger reduction in
assembly caused by competition, cf. SMN1 [blue line] and
SMN2 [red line]). Under conditions of competition with
SMN1 RNA, the intrinsic difference in U2 snRNP recruit-
ment between SMN1 and SMN2 RNAs was enhanced and
became more significant (Fig. 3D, P < 0.001). We conclude
that U2 snRNP assembly is more efficient on SMN1 than on
SMN2 transcripts, particularly under conditions of limited
availability of assembly factors.
Regulation of U2 snRNP recruitment after U2AF
binding
Previous work implicated the splicing regulatory factors
SF2/ASF and hnRNP A1 in the differential use of exon 7 in
SMN1 and SMN2: the C to T nucleotide difference at
exonic position 6 has been proposed to cause the loss of a
SF2/ASF-bound enhancer or/and the gain of a hnRNP A1-
bound silencer in SMN2 transcripts, consequently leading
to enhanced exon skipping (Cartegni and Krainer 2002;
Cartegni et al. 2006; Kashima and Manley 2003; Kashima
et al. 2007b). We therefore tested the effect of increasing
the levels of each of these splicing regulators on U2AF65
crosslinking to SMN1 and SMN2 RNAs. Figure 4A shows
the overall pattern of protein crosslinking. Addition of
recombinant purified SF2/ASF did not increase U2AF65
crosslinking to the SMN1 intron 6 39 splice site region (Fig.
4B, lanes 1,2), while it slightly increased crosslinking of
U2AF65 to SMN2 transcripts (Fig. 4B, lanes lanes 4,5). In
contrast, hnRNP A1 reduced U2AF65 crosslinking to SMN1
(Fig. 4B, cf. lanes 1 and 3), but not to SMN2 RNAs (Fig. 4B,
cf. lanes 4 and 6). These effects were reproduced in
independent experiments and the quantification of U2AF65
crosslinking, normalized to the levels of SMN1 crosslinking
in the absence of added factors, is presented in Figure 4C.
We conclude that SF2/ASF and hnRNP A1 display differ-
ential effects on U2AF65 crosslinking, and that these effects
depend on the nature of the 39 splice site of SMN1 and
SMN2 intron 6 (see Discussion).
Next, we tested the effects of increasing the levels of SF2/
ASF and hnRNP A1 on the complexes assembled on SMN1
and SMN2 transcripts. Addition of recombinant SF2/ASF
resulted in increased levels of A complex on both SMN1
and SMN2 transcripts, while addition of recombinant
hnRNP A1 resulted in decreased levels of A complex on
both transcripts (Fig. 4D).
Taken together, the results above indicate that regulatory
factors can target both U2AF65 binding as well as sub-
sequent steps in U2 snRNP assembly. To further explore
this concept, we used an antisense 29-O-methyl oligonu-
cleotide complementary to SMN exon 7 positions 21–35;
antisense oligonucleotides bound to this region have been
shown to block the function of a splicing enhancer (Hua
et al. 2007) recognized by Tra2-b1, SRp30C, hnRNP G, and
possibly other factors (Hofmann et al. 2000; Young et al.
2002; Hofmann and Wirth 2002). Addition of this oligo-
nucleotide, but not of a control, caused efficient inhibition
of U2 snRNP binding to both SMN1 and SMN2 RNAs (Fig.
4E). This was not accompanied by reduced U2AF65 cross-
linking (Fig. 4F, G), once again suggesting that certain
regulatory factors and sequences modulate U2 snRNP
recruitment to SMN transcripts at a step subsequent to
U2AF binding to the Py-tract.
DISCUSSION
Despite extensive analysis of cis-acting elements and trans-
acting factors relevant for SMN splicing, little was known
about how the critical nucleotide difference at position 6 of
exon 7 influences recognition of the upstream 39 splice site
of SMN1 and SMN2 transcripts by the basic splicing
machinery. This is, however, a relevant question to under-
stand the more efficient inclusion of exon 7 in SMN1
transcripts and eventually to design strategies that can
stimulate exon inclusion in SMN2 transcripts. Such strat-
egies have significant therapeutic promise based upon
results obtained in vitro and in animal models of SMA
(Cartegni and Krainer 2003; Skordis et al. 2003; Madocsai
et al. 2005; Coady et al. 2007; Hua et al. 2008).
Our results indicate that the C to U transition at exon 7
position 6 decreases U2AF association to the intron 6 39
splice site in SMN2 transcripts by about twofold (Fig. 2).
This difference in U2AF recruitment in vitro may represent
a significant alteration in the balance of splice-site choice
under in vivo conditions of 39 splice site cotranscriptional
competition, and therefore be responsible for the sub-
stantial difference in exon 7 inclusion between SMN1 and
SMN2 transcripts observed in vivo. Differential U2AF
recruitment correlates with a 1.6-fold lower efficiency of
U2 snRNP assembly on SMN2 transcripts (Fig. 3). The
difference in the fold reduction of U2AF65 crosslinking
and A complex formation may reflect the different set up of
the two assays: U2 snRNP assembly is monitored by
the retarded electrophoretic mobility of heparin-treated
complexes, while U2AF association is monitored by UV-
light-induced protein–RNA crosslinking, which is likely to
provide a snapshot of the occupancy of the RNA by
U2AF65.
Alternatively, U2AF65 binding may not be rate-limiting
for U2 snRNP recruitment to the SMN intron 6 39 splice site
(Hastings et al. 2007), and therefore the observed differences
in U2AF65 binding may not fully determine the extent of U2
snRNP recruitment. U2 snRNP binding involves base-
pairing interactions between U2 snRNA and the branch
point sequence that require U2AF (Valca´rcel et al. 1996).
Stable U2 binding, however, requires a number of addi-
tional factors and ATP-driven conformational changes that
may not directly depend on the levels of U2AF binding. In
this model, the higher efficiency of SMN1 exon 7 inclusion
Differential 39 splice site recognition of SMN
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could be related to differences in later events in spliceosome
assembly or even catalysis, consistent with observations in
other systems (Lallena et al. 2002; Lim and Hertel 2004;
House and Lynch 2006; Bonnal et al. 2008; Kotlajich et al.
2008; Sharma et al. 2008).
The differences in U2 snRNP association to the SMN1
and SMN2 intron 6 39 splice sites became more obvious
under conditions of limited availability of splicing factors
(using an excess of competing RNA substrates) (Fig. 3B,C).
Although it is unclear how these conditions relate to the
physiological situation in the cell nucleus, it is possible that
distinct features of U2 snRNP assembly on SMN1 and
SMN2 revealed by the competition assays of Figure 3C play
a role in the efficiency of exon 7 utilization under
conditions of cotranscriptional assembly in vivo. Taken
together, the results of UV crosslinking and spliceosome
assembly assays suggest that both U2AF binding and U2
snRNP assembly on SMN1 and SMN2 transcripts are
distinguishable, at least under particular experimental
conditions.
Previous work implicated the SR protein SF2/ASF and
the hnRNP A1 protein in the differential splicing of SMN
transcripts. One model proposed that the C to T +6
transition leads to loss of a SF2/ASF-dependent splicing
enhancer in SMN2 exon 7 RNAs (Cartegni and Krainer
2002; Cartegni et al. 2006). The second, not necessarily
mutually exclusive, model proposed the gain of a hnRNP
A1-dependent splicing silencer (Kashima and Manley 2003;
Cartegni et al. 2006; Kashima et al. 2007b). One simple
mechanism for the function of these factors would be that
their association with SMN1 or SMN2 exon 7 promotes or
represses recognition of the 39 splice site by U2AF. This
model predicts that SF2/ASF would stimulate U2AF bind-
ing to SMN1, but not to SMN2 transcripts, while hnRNP
FIGURE 4. Differential effects of SF2/ASF and hnRNPA1 on U2AF65 crosslinking and spliceosome assembly to SMN transcripts. (A) Pattern of
proteins crosslinked to SMN transcripts upon addition of recombinant purified SF2/ASF or hnRNP A1 (0.4 pmol/mL). (B) Crosslinking/
immunoprecipitation of U2AF65 in assays as in A, carried out as in Figure 2C. (C) PhosphorImager quantification of signals corresponding to
U2AF65 precipitates obtained in independent experiments as in B. (D) Spliceosomal complexes assembled on SMN transcripts in the absence or
presence of recombinant SF2/ASF or hnRNP A1, as in B. Complexes assembled on SMN1 and SMN2 RNAs after incubation with nuclear extract
and the indicated proteins for 30 min were resolved by electrophoresis on native polyacrylamide/agarose gels. Signals from A and H complexes
were quantified by PhosphorImager analysis and the ratios represented at the bottom of the figure. (E) Spliceosomal complexes assembled on
SMN transcripts in the presence of 125 nM of a 29-O-methyl oligonucleotide complementary to the Tra2-b1 enhancer located in exon 7 positions
21–35 (59-GAGCACCTTCCTTCT-39) or a control (Ctr) oligonucleotide (59-ATTAGTGGAATTGGC-39), analyzed as in D. (F) Crosslinking/
immunoprecipitation of U2AF65 in assays as in E, carried out as in Figure 2C. (G) Ratio between U2AF65 crosslinking in the presence of Tra2-b1
enhancer antisense and control oligos from PhosphorImager quantification of signals corresponding to U2AF65 precipitates obtained in three
independent experiments as in F.
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A1 would decrease U2AF binding to SMN2, but not to
SMN1 RNAs. The results of Figure 4, however, show the
opposite trend: increasing the levels of SF2/ASF increases
U2AF65 crosslinking to SMN2, but not to SMN1 tran-
scripts; and increased levels of hnRNP A1 reduce cross-
linking of U2AF65 to SMN1, but not to SMN2 RNAs. One
possible explanation for these results is that SF2/ASF
binding to SMN1, and that of hnRNP A1 to SMN2, are
saturated (Cartegni et al. 2006), and therefore, that increas-
ing their levels in the assays does not further enhance the
difference in U2AF65 association to SMN1 and SMN2
detected in our crosslinking assays under normal condi-
tions. Increasing the levels of SF2/ASF could, however,
enhance its association with SMN2 transcripts (for which
the presence of uridine at position +6 represents a sub-
optimal SF2/ASF binding site), perhaps decreasing hnRNP
A1 binding, and thus increasing U2AF65 recruitment. Con-
versely, increasing the levels of hnRNP A1 could enhance
its association with SMN1 transcripts (for which the cy-
tidine at position 6 represents a suboptimal binding site),
perhaps decreasing SF2/ASF binding and decreasing U2AF65
recruitment to these RNAs.
The results of Figure 4D indicate that SF2/ASF stim-
ulates, while hnRNP A1 decreases, U2 snRNP binding to
both SMN1 and SMN2. SF2/ASF-dependent stimulation of
U2 recruitment to SMN2 transcripts (Fig. 4D) correlates
with enhanced U2AF binding (Fig. 4B,C), whereas, stronger
U2 recruitment to SMN1 transcripts does not. These results
suggest that an excess of SF2/ASF stimulates other steps in
SMN1 39 splice site recognition by U2 snRNP. Similarly,
decreased U2 recruitment to SMN1 transcripts by hnRNP
A1 (Fig. 3C) correlates with reduced U2AF binding (Fig.
3B,C), while the decrease in U2 binding to SMN2 does not.
The latter result suggests that other steps in U2 snRNP
binding would be decreased by hnRNP A1 in SMN2 RNAs,
as observed for other transcripts (Tange et al. 2001). A
possible common explanation for these observations would
be that the effects of SF2/ASF and hnRNP A1, when
mediated through sequences involving position +6, affect
steps in U2 snRNP recruitment other than U2AF binding.
In contrast, effects mediated through other SF2/ASF and
hnRNP A1 binding sites within exon 7 or flanking
sequences influence U2 snRNP recruitment through mod-
ulation of U2AF binding.
The observation that an antisense oligonucletide that
blocks the function of a Tra2-b1-dependent exonic
enhancer inhibits U2 snRNP recruitment without affecting
U2AF65 binding (Fig. 4E–G) is consistent with similar
observations made for SR protein-dependent exonic
enhancers (Shen et al. 2004).
Collectively, the results presented in this manuscript
suggest that both U2AF binding and other steps required
for stable assembly of U2 snRNP at the branch site can be
affected by the single nucleotide difference in exon 7
position 6 between SMN1 and SMN2 transcripts. They also
suggest that trans-acting factors like SF2/ASF and hnRNP
A1 can target these different steps in a transcript-specific
manner.
MATERIALS AND METHODS
RNAs
pCISMNxD-wt or pCISMNxD-c6t (Cartegni and Krainer 2002)
were used to transcribe SMN1 and SMN2 RNAs. Py-mut con-
structs were obtained by replacing the thymidine residues con-
tained in the polypyrimidine tract by cytidines via PCR-based site-
directed mutagenesis of pCI plasmids as described by Hemsley
et al. (1989) using 59-phosphorylated oligonucleotides. Templates
used to generate transcripts containing the 39 68 nt of intron 6, the
complete sequence of exon 7 and 26 nt of intron 7 were generated
by PCR using primers SMNCXLFor 59-CGTAATACGACTCAC
TATAGGGCTATCTATATATAGCTATC-39 and SMNCXLBack
59-CACTTTCATAATGCTGGCAG-39. RNAs were synthesized from
400 ng of PCR templates in 25 mL transcription reactions
containing 40 mM Tris-HCl (pH 7.9), 10 mM NaCl, 6 mM
MgCl2, 2 mM spermidine, 0.8 mM DTT, 0.4mM ATP, CTP, and
GTP, 0.08 mM UTP, 36 U of T7 RNA polymerase and 50 mCi
[a-32P]UTP (Amersham). Full-length substrates were transcribed
in the presence of 1.9 mM CAP-analog (m7G[5])ppp[59]G) (New
England Biolabs) and GTP was at 0.04 mM final concentration.
Reactions were incubated for 2 h at 37°C and transcription
products were gel-purified.
Protein expression
GST-U2AF65, SF2/ASF, and hnRNP A1 were expressed in and
purified from E. coli using previously published procedures
(Mayeda and Krainer 1992; Valca´rcel et al. 1996) and gel-
quantified by comparing dilutions of the preparations to a BSA
standard.
In vitro splicing and spliceosome assembly assays
Pre-mRNA substrates (10 fmol) were incubated in 10 mL reaction
mixtures containing HeLa nuclear extract, 32 mM HEPES (pH
7.9), 1.56 mM MgCl2, 0.5 mM ATP, 20 mM creatine phosphate,
and 2.6% polyvinyl alcohol. For in vitro splicing assays, reactions
were incubated at 30°C for 2 h; RNA was extracted and analyzed
on 9% denaturing polyacrylamide gels. Gels were exposed to a
PhosphorImager screen. For spliceosome assembly analysis, reac-
tions were incubated at 30°C for 30 min, unless otherwise stated,
and then treated with heparin (5 mg/mL). Complexes were
separated on 4% acrylamide:bisacrylamide (80:1)–0.5% agarose
gels in 50 mM Tris base-50 mM glycine buffer. Dried gels were
exposed to a PhosphorImager screen.
UV crosslinking and immunoprecipitation of U2AF65
Pre-mRNAs were incubated under the same conditions as
described for in vitro splicing and spliceosome assembly assays,
except that the reaction volume was increased to 25 mL. After 30
min of incubation at 30°C, samples were UV-irradiated (254 nm,
0.4J, 1.7 cm from light source) and treated with RNase A (1 mg/
mL, final concentration) at 37°C for 30 min. A 10% aliquot of the
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crosslinked samples was loaded onto a 10% SDS-PAGE. To
immunoprecipitate U2AF65, 50 mL of anti-U2AF65 monoclonal
antibody, MC3 (Gama-Carvalho et al. 1997), was added to 90% of
the crosslinked material, and 0.1 M KCl Buffer D (20 mM HEPES
[pH 8.0], 0.5 mM EDTA, 20% glycerol, 1 mM DTT, 0.05% NP-
40) was added to a final volume of 120 mL. Monoclonal antibody
104 (Roth et al. 1990) was used for mock-immunoprecipitation.
Antibody and antigen were allowed to react on ice for 1 h with
periodic swirling. After addition of 50 mL of a 1:1 slurry of Protein
A + Protein G Sepharose 4 Fast Flow (at 1:1 proportion;
Amersham) in low salt buffer (50 mM Tris-HCl [pH 8.0], 150
mM NaCl, 1% NP-40), samples were incubated at 4°C with
rotation for 1 h Beads were washed three times with high salt
buffer (50 mM Tris-HCl [pH 8.0], 500 mM NaCl, 1% NP-40) and
three times with low salt buffer and resuspended in 10 mL of SDS-
loading dye and boiled for 5 min. After centrifugation, the superna-
tant was loaded on a 10% SDS-polycrylamide gel. Dried gels were
exposed to a PhosphorImager screen and signals quantified with
ImageQuant TL software (Amersham Biosciences).
SUPPLEMENTAL MATERIAL
Supplemental material can be found at http://www.rnajournal.org.
ACKNOWLEDGMENTS
M.M.d.A. was supported by a fellowship from the Portuguese
Foundation of Science and Tecnhology (FCT), from the Graduate
Programme in Areas of Basic and Applied Biology (GABBA).
Work in J.V.’s laboratory is supported by grants from AICR,
Ministerio de Educacio´n y Ciencia, EURASNET and Fundacio´n
Marcelino Botı´n. Work in A.R.K.’s laboratory was supported by
NIH Grant GM42699.
Received July 16, 2008; accepted January 14, 2009.
REFERENCES
Blanchette, M. and Chabot, B. 1999. Modulation of exon skipping by
high-affinity hnRNP A1-binding sites and by intron elements that
repress splice site utilization. EMBO J. 18: 1939–1952.
Bonnal, S., Martı´nez, C., Fo¨rch, P., Bachi, A., Wilm, M., and
Valca´rcel, J. 2008. RBM5/Luca-15/H37 regulates Fas alternative
splice site pairing after exon definition. Mol. Cell 32: 81–95.
Brzustowicz, L.M., Lehner, T., Castilla, L.H., Penchaszadeh, G.K.,
Wilhelmsen, K.C., Daniels, R., Davies, K.E., Leppert, M., Ziter, F.,
Wood, D., et al. 1990. Genetic mapping of chronic childhood-
onset spinal muscular atrophy to chromosome 5q11.2–13.3.
Nature 344: 540–541.
Cartegni, L. and Krainer, A.R. 2002. Disruption of an SF2/ASF-
dependent exonic splicing enhancer in SMN2 causes spinal
muscular atrophy in the absence of SMN1. Nat. Genet. 30: 377–
384.
Cartegni, L. and Krainer, A.R. 2003. Correction of disease-associated
exon skipping by synthetic exon-specific activators. Nat. Struct.
Biol. 10: 120–125.
Cartegni, L., Hastings, M.L., Calarco, J.A., De Stanchina, E., and
Krainer, A.R. 2006. Determinants of exon 7 splicing in the spinal
muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 78:
63–77.
Chew, S.L., Liu, H.X., Mayeda, A., and Krainer, A.R. 1999. Evidence
for the function of an exonic splicing enhancer after the first
catalytic step of pre-mRNA splicing. Proc. Natl. Acad. Sci. 96:
10655–10660.
Coady, T.H., Shababi, M., Tullis, G.E., and Lorson, C.L. 2007.
Restoration of SMN function: Delivery of a trans-splicing RNA
re-directs SMN2 pre-mRNA splicing. Mol. Ther. 15: 1471–1478.
Eperon, I.C., Makarova, O.V., Mayeda, A., Munroe, S.H.,
Caceres, J.F., Hayward, D.G., and Krainer, A.R. 2000. Selection
of alternative 59 splice sites: Role of U1 snRNP and models for the
antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20:
8303–8318.
Gama-Carvalho, M., Krauss, R.D., Chiang, L., Valca´rcel, J.,
Green, M.R., and Carmo-Fonseca, M. 1997. Targeting of U2AF65
to sites of active splicing in the nucleus. J. Cell Biol. 137: 975–987.
Gubitz, A.K., Feng, W., and Dreyfuss, G. 2004. The SMN complex.
Exp. Cell Res. 296: 51–56.
Guth, S., Martinez, C., Gaur, R.K., and Valca´rcel, J. 1999. Evidence for
substrate-specific requirement of the splicing factor U2AF35 and
for its function after polypyrimidine tract recognition by U2AF65.
Mol. Cell. Biol. 19: 8263–8271.
Hastings, M.L., Allemand, E., Duelli, D.M., Myers, M.P., and
Krainer, A.R. 2007. Control of pre-mRNA splicing by the general
splicing factors PUF60 and U2AF65. PLoS One 2: e538. doi:
10.1371/journal.pone.0000538.
Hemsley, A., Arnheim, N., Toney, M.D., Cortopassi, G., and
Galas, D.J. 1989. A simple method for site-directed mutagenesis
using the polymerase chain reaction. Nucleic Acids Res. 17: 6545–
6551.
Hofmann, Y. and Wirth, B. 2002. hnRNP-G promotes exon 7
inclusion of survival motor neuron (SMN) via direct interaction
with Htra2-b1. Hum. Mol. Genet. 11: 2037–2049.
Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J., and Wirth, B.
2000. Htra2-b1 stimulates an exonic splicing enhancer and can
restore full-length SMN expression to survival motor neuron 2
(SMN2). Proc. Natl. Acad. Sci. 97: 9618–9623.
House, A.E. and Lynch, K.W. 2006. An exonic splicing silencer
represses spliceosome assembly after ATP-dependent exon recog-
nition. Nat. Struct. Mol. Biol. 13: 937–944.
Hua, Y., Vickers, T.A., Baker, B.F., Bennett, C.F., and Krainer, A.R.
2007. Enhancement of SMN2 exon 7 inclusion by antisense
oligonucleotides targeting the exon. PLoS Biol. 5: e73. doi:
10.1371/journal.pbio.0050073.
Hua, Y., Vickers, T.A., Okunola, H.L., Bennett, C.F., and Krainer, A.R.
2008. Antisense masking of an hnRNP A1/A2 intronic splicing
silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum.
Genet. 82: 834–848.
Kan, J.L. and Green, M.R. 1999. Pre-mRNA splicing of IgM exons M1
and M2 is directed by a juxtaposed splicing enhancer and
inhibitor. Genes & Dev. 13: 462–471.
Kashima, T. and Manley, J.L. 2003. A negative element in SMN2 exon 7
inhibits splicing in spinal muscular atrophy. Nat. Genet. 34: 460–463.
Kashima, T., Rao, N., and Manley, J.L. 2007a. An intronic element
contributes to splicing repression in spinal muscular atrophy. Proc.
Natl. Acad. Sci. 104: 3426–3431.
Kashima, T., Rao, N., David, C.J., and Manley, J.L. 2007b. hnRNP A1
functions with specificity in repression of SMN2 exon 7 splicing.
Hum. Mol. Genet. 16: 3149–3159.
Kotlajich, M.V., Crabb, T.L., and Hertel, K.J. 2008. Spliceosome
assembly pathways for different types of alternative splicing
converge during commitment to splice site pairing in A complex.
Mol. Cell. Biol. Epub ahead of print.
Lallena, M.J., Chalmers, K., Llamazares, S., Lamond, A.I., and
Valca´rcel, J. 2002. Splicing regulation at the second catalytic step
by Sex-lethal involves 39 splice site recognition by SPF45. Cell 109:
285–296.
Le, T.T., Pham, L.T., Butchbach, M.E., Zhang, H.L., Monani, U.R.,
Coovert, D.D., Gavrilina, T.O., Xing, L., Bassell, G.J., and
Burghes, A.H. 2005. SMNd7, the major product of the centromeric
survival motor neuron (SMN2) gene, extends survival in mice with
Martins de Arau´jo et al.
522 RNA, Vol. 15, No. 4
 Cold Spring Harbor Laboratory Press on November 9, 2017 - Published by rnajournal.cshlp.orgDownloaded from 
spinal muscular atrophy and associates with full-length SMN.
Hum. Mol. Genet. 14: 845–857.
Lee, C.G., Zamore, P.D., Green, M.R., and Hurwitz, J. 1993. RNA
annealing activity is intrinsically associated with U2AF. J. Biol.
Chem. 268: 13472–13478.
Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P.,
Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et
al. 1995. Identification and characterization of a spinal muscular
atrophy-determining gene. Cell 80: 155–165.
Lim, J.R. and Hertel, K.J. 2004. Commitment to splice site pairing
coincides with A complex formation. Mol. Cell 15: 477–483.
Lin, S. and Fu, X.D. 2007. SR proteins and related factors in
alternative splicing. Adv. Exp. Med. Biol. 623: 107–122.
Lorson, C.L., Hahnen, E., Androphy, E.J., and Wirth, B. 1999. A single
nucleotide in the SMN gene regulates splicing and is responsible
for spinal muscular atrophy. Proc. Natl. Acad. Sci. 96: 6307–6311.
Lutzelberger, M., Backstrom, E., and Akusjarvi, G. 2005. Substrate-
dependent differences in U2AF requirement for splicing in
adenovirus-infected cell extracts. J. Biol. Chem. 280: 25478–25484.
MacMillan, A.M., McCaw, P.S., Crispino, J.D., and Sharp, P.A. 1997.
SC35-mediated reconstitution of splicing in U2AF-depleted
nuclear extract. Proc. Natl. Acad. Sci. 94: 133–136.
Madocsai, C., Lim, S.R., Geib, T., Lam, B.J., and Hertel, K.J. 2005.
Correction of SMN2 pre-mRNA splicing by antisense U7 small
nuclear RNAs. Mol. Ther. 12: 1013–1022.
Mailman, M.D., Heinz, J.W., Papp, A.C., Snyder, P.J., Sedra, M.S.,
Wirth, B., Burghes, A.H., and Prior, T.W. 2002. Molecular analysis
of spinal muscular atrophy and modification of the phenotype by
SMN2. Genet. Med. 4: 20–26.
Mayeda, A. and Krainer, A. 1992. Regulation of alternative pre-mRNA
splicing by hnRNP A1 and splicing factor SF2. Cell 68: 365–375.
Melki, J., Sheth, P., Abdelhak, S., Burlet, P., Bachelot, M.F.,
Lathrop, M.G., Frezal, J., and Munnich, A. 1990. Mapping of
acute (type I) spinal muscular atrophy to chromosome 5q12–q14.
The French Spinal Muscular Atrophy Investigators. Lancet 336:
271–273.
Monani, U.R., Lorson, C.L., Parsons, D.W., Prior, T.W.,
Androphy, E.J., Burghes, A.H., and McPherson, J.D. 1999. A
single nucleotide difference that alters splicing patterns distin-
guishes the SMA gene SMN1 from the copy gene SMN2. Hum.
Mol. Genet. 8: 1177–1183.
Roth, M.B., Murphy, C., and Gall, J.G. 1990. A monoclonal antibody
that recognizes a phosphorylated epitope stains lampbrush chro-
mosome loops and small granules in the amphibian germinal
vesicle. J. Cell Biol. 111: 2217–2223.
Russman, B.S. 2007. Spinal muscular atrophy: Clinical classification
and disease heterogeneity. J. Child Neurol. 22: 946–951.
Sharma, S., Kohlstaedt, L.A., Damianov, A., Rio, D.C., and Black, D.L.
2008. Polypyrimidine tract binding protein controls the transition
from exon definition to an intron defined spliceosome. Nat. Struct.
Mol. Biol. 15: 183–191.
Shen, H. and Green, M.R. 2004. A pathway of sequential arginine-
serine-rich domain-splicing signal interactions during mammalian
spliceosome assembly. Mol. Cell 16: 363–373.
Shen, H., Kan, J.L., and Green, M.R. 2004. Arginine-serine-rich
domains bound at splicing enhancers contact the branch-point
to promote prespliceosome assembly. Mol. Cell 13: 367–376.
Singh, N.K., Singh, N.N., Androphy, E.J., and Singh, R.N. 2006.
Splicing of a critical exon of human survival motor neuron is
regulated by a unique silencer element located in the last intron.
Mol. Cell. Biol. 26: 1333–1346.
Singh, N.N., Androphy, E.J., and Singh, R.N. 2004. An extended
inhibitory context causes skipping of exon 7 of SMN2 in spinal
muscular atrophy. Biochem. Biophys. Res. Commun. 315: 381–388.
Singh, R. and Valca´rcel, J. 2005. Building specificity with nonspecific
RNA-binding proteins. Nat. Struct. Mol. Biol. 12: 645–653.
Singh, R., Valca´rcel, J., and Green, M.R. 1995. Distinct binding
specificities and functions of higher eukaryotic polypyrimidine
tract-binding proteins. Science 268: 1173–1176.
Singh, R.N. 2007. Evolving concepts on human SMN pre-mRNA
splicing. RNA Biol. 4: 7–10.
Skordis, L.A., Dunckley, M.G., Yue, B., Eperon, I.C., and Muntoni, F.
2003. Bifunctional antisense oligonucleotides provide a trans-
acting splicing enhancer that stimulates SMN2 gene expression
in patient fibroblasts. Proc. Natl. Acad. Sci. 100: 4114–4119.
Sridharan, V. and Singh, R. 2007. A conditional role of U2AF in
splicing of introns with unconventional polypyrimidine tracts.
Mol. Cell. Biol. 27: 7334–7344.
Tange, T.O., Damgaard, C.K., Guth, S., Valca´rcel, J., and Kjems, J.
2001. The hnRNP A1 protein regulates HIV-1 tat splicing via a
novel intron silencer element. EMBO J. 20: 5748–5758.
Tisserant, A. and Ko¨nig, H. 2008. Signal regulated pre-mRNA
occupancy by the general splicing factor U2AF. PLoS One 3:
e1418. doi: 10.1371/journal.pone.00001418.
Valca´rcel, J., Gaur, R.K., Singh, R., and Green, M.R. 1996. Interaction
of U2AF65 RS region with pre-mRNA branch point and pro-
motion of base pairing with U2 snRNA. Science 273: 1706–1709.
Wagner, E.J. and Garcia-Blanco, M.A. 2001. Polypyrimidine tract
binding protein antagonizes exon definition. Mol. Cell. Biol. 21:
3281–3288.
Will, C.L. and Lu¨hrmann, R. 2005. Spliceosome structure and
function. In RNA world III (eds. R.F. Gesteland and T.R. Cech,
Atkins, J.F.), pp. 369–400. Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY.
Young, P.J., DiDonato, C.J., Hu, D., Kothary, R., Androphy, E.J., and
Lorson, C.L. 2002. SRp30c-dependent stimulation of survival
motor neuron (SMN) exon 7 inclusion is facilitated by a direct
interaction with hTra2 b1. Hum. Mol. Genet. 11: 577–587.
Zhang, Z., Lotti, F., Dittmar, K., Younis, I., Wan, L., Kasim, M., and
Dreyfuss, G. 2008. SMN deficiency causes tissue-specific pertur-
bations in the repertoire of snRNAs and widespread defects in
splicing. Cell 133: 585–600.
Zhu, J. and Krainer, A.R. 2000. Pre-mRNA splicing in the absence of
an SR protein RS domain. Genes & Dev. 14: 3166–3178.
Zhu, J., Mayeda, A., and Krainer, A.R. 2001. Exon identity estab-
lished through differential antagonism between exonic splicing
silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol.
Cell 8: 1351–1361.
Zuo, P. and Maniatis, T. 1996. The splicing factor U2AF35 mediates
critical protein–protein interactions in constitutive and enhancer-
dependent splicing. Genes & Dev. 10: 1356–1368.
Differential 39 splice site recognition of SMN
www.rnajournal.org 523
 Cold Spring Harbor Laboratory Press on November 9, 2017 - Published by rnajournal.cshlp.orgDownloaded from 
 10.1261/rna.1273209Access the most recent version at doi:
 2009 15: 515-523 originally published online February 25, 2009RNA
  
Mafalda Martins de Araújo, Sophie Bonnal, Michelle L. Hastings, et al. 
  
U2AF and U2 snRNP
 transcripts bySMN2 and SMN1 splice site recognition of ′Differential 3
  
Material
Supplemental
  
 http://rnajournal.cshlp.org/content/suppl/2009/02/26/rna.1273209.DC1
  
References
  
 http://rnajournal.cshlp.org/content/15/4/515.full.html#ref-list-1
This article cites 58 articles, 22 of which can be accessed free at:
  
License
Service
Email Alerting
  
 click here.top right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://rnajournal.cshlp.org/subscriptions
 go to: RNATo subscribe to 
Copyright © 2009 RNA Society
 Cold Spring Harbor Laboratory Press on November 9, 2017 - Published by rnajournal.cshlp.orgDownloaded from 
